Home » Stocks » VCYT

Veracyte, Inc. (VCYT)

Stock Price: $50.79 USD -1.79 (-3.40%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 2.94B
Revenue (ttm) 112.68M
Net Income (ttm) -34.32M
Shares Out 54.86M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $50.79
Previous Close $52.58
Change ($) -1.79
Change (%) -3.40%
Day's Open 52.48
Day's Range 50.54 - 54.66
Day's Volume 605,331
52-Week Range 16.13 - 61.88

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference

Zacks Investment Research - 3 weeks ago

Veracyte (VCYT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Business Wire - 4 weeks ago

WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Veracyte (Nasdaq:VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Pro...

Other stocks mentioned: BAYRY
Seeking Alpha - 4 weeks ago

Veracyte has been able to show a strong recovery after struggling through the COVID-19 headwinds of Q2. Now, the company is looking to fill the gap and surpass 2019's numbers. I take a look at...

Business Wire - 4 weeks ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte received ISO 13485:2016 certification for the company's in vitro diagnostics Quality Management System.

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020

Business Wire - 1 month ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New General Manager Structure to Advance Global Expansion

Seeking Alpha - 2 months ago

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Veracyte (VCYT) delivered earnings and revenue surprises of 55.56% and 25.24%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Third Quarter 2020 Financial Results

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Prosigna Breast Cancer Test Data Published in Journal of Clinical Oncology

Zacks Investment Research - 2 months ago

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 2 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier

Business Wire - 3 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting

Business Wire - 3 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020

Business Wire - 3 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020

Business Wire - 3 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the Centers for Medicare and Medicaid Services (CMS) has approved new Advanced Diagnostic Labor...

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at Two Investor Conferences

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Promotion of Richard T.

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Initiates Study to Generate Consensus on Medical Utility of Multiple Breast Cancer Genomic Tests

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Present at Upcoming Investor Conferences

Business Wire - 4 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announces positive clinical utility data for Percepta classifier published online in CHEST

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc.

Seeking Alpha - 5 months ago

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Veracyte (VCYT) delivered earnings and revenue surprises of 0.00% and 17.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Second Quarter 2020 Financial Results

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Data Published in AJRCCM Showing that the Envisia Genomic Classifier Improves Physicians’ Ability to Diagnose IPF Without Surgery

Business Wire - 5 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary

Investors Business Daily - 6 months ago

Veracyte sees its Relative Strength Rating move into the 80-plus level. The post Veracyte Clears Technical Benchmark, Hitting 80-Plus RS Rating appeared first on Investor's Business Daily.

Business Wire - 6 months ago

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020

Investors Business Daily - 7 months ago

A Relative Strength Rating upgrade for Veracyte shows improving technical performance. Will it continue?

Seeking Alpha - 8 months ago

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Veracyte (VCYT) delivered earnings and revenue surprises of -33.33% and 2.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Veracyte (VCYT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Investors Business Daily - 9 months ago

A Relative Strength Rating upgrade for Veracyte shows improving technical performance. Will it continue?

Seeking Alpha - 10 months ago

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Veracyte (VCYT) delivered earnings and revenue surprises of -66.67% and 1.28%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 11 months ago

Genome testing is exploding on a global level; these companies are saving lives and making money.

Other stocks mentioned: EXAS
Seeking Alpha - 11 months ago

Veracyte, Inc.: An Undervalued Odds-On Near-Term Capital-Gainer

Seeking Alpha - 1 year ago

Veracyte: Adding Another Big Pharma Partner Backs Bullish Outlook

Investopedia - 1 year ago

As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.

Other stocks mentioned: CRSP, EDIT, GH, ILMN, NTLA, NVTA, RGNX
Seeking Alpha - 1 year ago

Veracyte, Inc. (VCYT) CEO Bonnie Anderson on Q3 2019 Earnings Call Transcript

About VCYT

Veracyte operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for sur... [Read more...]

Industry
Biotechnology
IPO Date
Oct 30, 2013
CEO
Bonnie Anderson
Employees
354
Stock Exchange
NASDAQ
Ticker Symbol
VCYT
Full Company Profile

Financial Performance

In 2019, Veracyte's revenue was $120.37 million, an increase of 30.82% compared to the previous year's $92.01 million. Losses were -$12.60 million, -45.22% less than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Veracyte stock is "Buy." The 12-month stock price forecast is 46.20, which is a decrease of -9.04% from the latest price.

Price Target
$46.20
(-9.04% downside)
Analyst Consensus: Buy